• Something wrong with this record ?

ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance

S. Drápela, J. Bouchal, MK. Jolly, Z. Culig, K. Souček,

. 2020 ; 7 (-) : 36. [pub] 20200319

Language English Country Switzerland

Document type Journal Article, Review

The predominant way in which conventional chemotherapy kills rapidly proliferating cancer cells is the induction of DNA damage. However, chemoresistance remains the main obstacle to therapy effectivity. An increasing number of studies suggest that epithelial-to-mesenchymal transition (EMT) represents a critical process affecting the sensitivity of cancer cells to chemotherapy. Zinc finger E-box binding homeobox 1 (ZEB1) is a prime element of a network of transcription factors controlling EMT and has been identified as an important molecule in the regulation of DNA damage, cancer cell differentiation, and metastasis. Recent studies have considered upregulation of ZEB1 as a potential modulator of chemoresistance. It has been hypothesized that cancer cells undergoing EMT acquire unique properties that resemble those of cancer stem cells (CSCs). These stem-like cells manifest enhanced DNA damage response (DDR) and DNA repair capacity, self-renewal, or chemoresistance. In contrast, functional experiments have shown that ZEB1 induces chemoresistance regardless of whether other EMT-related changes occur. ZEB1 has also been identified as an important regulator of DDR by the formation of a ZEB1/p300/PCAF complex and direct interaction with ATM kinase, which has been linked to radioresistance. Moreover, ATM can directly phosphorylate ZEB1 and enhance its stability. Downregulation of ZEB1 has also been shown to reduce the abundance of CHK1, an effector kinase of DDR activated by ATR, and to induce its ubiquitin-dependent degradation. In this perspective, we focus on the role of ZEB1 in the regulation of DDR and describe the mechanisms of ZEB1-dependent chemoresistance.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019439
003      
CZ-PrNML
005      
20230119094531.0
007      
ta
008      
201103s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fmolb.2020.00036 $2 doi
035    __
$a (PubMed)32266287
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Drápela, Stanislav $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czechia. International Clinical Research Center, Center for Biomolecular and Cellular Engineering, St. Anne's University Hospital in Brno, Brno, Czechia. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czechia. $7 xx0280838
245    10
$a ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance / $c S. Drápela, J. Bouchal, MK. Jolly, Z. Culig, K. Souček,
520    9_
$a The predominant way in which conventional chemotherapy kills rapidly proliferating cancer cells is the induction of DNA damage. However, chemoresistance remains the main obstacle to therapy effectivity. An increasing number of studies suggest that epithelial-to-mesenchymal transition (EMT) represents a critical process affecting the sensitivity of cancer cells to chemotherapy. Zinc finger E-box binding homeobox 1 (ZEB1) is a prime element of a network of transcription factors controlling EMT and has been identified as an important molecule in the regulation of DNA damage, cancer cell differentiation, and metastasis. Recent studies have considered upregulation of ZEB1 as a potential modulator of chemoresistance. It has been hypothesized that cancer cells undergoing EMT acquire unique properties that resemble those of cancer stem cells (CSCs). These stem-like cells manifest enhanced DNA damage response (DDR) and DNA repair capacity, self-renewal, or chemoresistance. In contrast, functional experiments have shown that ZEB1 induces chemoresistance regardless of whether other EMT-related changes occur. ZEB1 has also been identified as an important regulator of DDR by the formation of a ZEB1/p300/PCAF complex and direct interaction with ATM kinase, which has been linked to radioresistance. Moreover, ATM can directly phosphorylate ZEB1 and enhance its stability. Downregulation of ZEB1 has also been shown to reduce the abundance of CHK1, an effector kinase of DDR activated by ATR, and to induce its ubiquitin-dependent degradation. In this perspective, we focus on the role of ZEB1 in the regulation of DDR and describe the mechanisms of ZEB1-dependent chemoresistance.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bouchal, Jan $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czechia.
700    1_
$a Jolly, Mohit Kumar $u Centre for BioSystems Science and Engineering, Indian Institute of Science, Bangalore, India.
700    1_
$a Culig, Zoran $u International Clinical Research Center, Center for Biomolecular and Cellular Engineering, St. Anne's University Hospital in Brno, Brno, Czechia. Department of Urology, Experimental Urology, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Souček, Karel $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czechia. International Clinical Research Center, Center for Biomolecular and Cellular Engineering, St. Anne's University Hospital in Brno, Brno, Czechia. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czechia.
773    0_
$w MED00188065 $t Frontiers in molecular biosciences $x 2296-889X $g Roč. 7, č. - (2020), s. 36
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32266287 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20230119094524 $b ABA008
999    __
$a ind $b bmc $g 1586216 $s 1109637
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 7 $c - $d 36 $e 20200319 $i 2296-889X $m Frontiers in molecular biosciences $n Front Mol Biosci $x MED00188065
LZP    __
$a Pubmed-20201103

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...